Virbac Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Virbac wird ein jährliches Gewinn- und Umsatzwachstum von 10.8% bzw. 5.9% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 10.6% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 13.9% betragen.

Wichtige Informationen

10.8%

Wachstumsrate der Gewinne

10.6%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	5.9%
Zukünftige Eigenkapitalrendite	13.9%
Analystenabdeckung	Good
Zuletzt aktualisiert	22 Nov 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Virbac SA Just Beat Revenue Estimates By 6.0%

Sep 18

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Mar 22

Recent updates

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Mar 22

Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?

Jan 18

Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up

Dec 27

Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet

Oct 19

Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?

Sep 26

Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Sep 05

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Jun 20

Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?

May 31

Is Virbac (EPA:VIRP) Using Too Much Debt?

Apr 09

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?

Feb 28

Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 25

Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?

Oct 14

An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued

Aug 07

These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely

Jun 26

Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate

May 01

We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease

Mar 26

Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate

Jan 26

Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock

Dec 28

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Oct 27

Is Virbac (EPA:VIRP) Using Too Much Debt?

Oct 12

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Sep 26

Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?

Jul 15

Is Now The Time To Put Virbac (EPA:VIRP) On Your Watchlist?

Jun 27

Is Virbac (EPA:VIRP) A Risky Investment?

May 27

Robust Earnings May Not Tell The Whole Story For Virbac (EPA:VIRP)

Mar 24

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 32%?

Mar 12

Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Feb 22

Is Virbac SA (EPA:VIRP) Popular Amongst Insiders?

Feb 03

Virbac SA's (EPA:VIRP) Stock Is Going Strong: Is the Market Following Fundamentals?

Jan 05

Does Virbac's (EPA:VIRP) Share Price Gain of 96% Match Its Business Performance?

Dec 18

Gewinn- und Umsatzwachstumsprognosen

ENXTPA:VIRP - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (EUR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
12/31/2026	1,566	185	127	229	7
12/31/2025	1,483	166	107	201	8
12/31/2024	1,401	150	79	172	9
6/30/2024	1,339	141	74	139	N/A
3/31/2024	1,293	131	66	129	N/A
12/31/2023	1,247	121	59	119	N/A
9/30/2023	1,229	120	69	124	N/A
6/30/2023	1,210	119	78	129	N/A
3/31/2023	1,213	121	62	114	N/A
12/31/2022	1,216	122	45	99	N/A
9/30/2022	1,184	120	38	91	N/A
6/30/2022	1,151	119	31	84	N/A
3/31/2022	1,107	116	57	107	N/A
12/31/2021	1,064	113	83	130	N/A
9/30/2021	1,025	137	80	122	N/A
6/30/2021	985	161	77	113	N/A
3/31/2021	960	148	83	116	N/A
12/31/2020	934	136	90	119	N/A
9/30/2020	944	104	106	133	N/A
6/30/2020	953	72	123	146	N/A
3/31/2020	946	62	116	139	N/A
12/31/2019	938	52	109	132	N/A
9/30/2019	921	43	92	119	N/A
6/30/2019	903	34	76	106	N/A
3/31/2019	886	27	63	95	N/A
12/31/2018	869	20	50	84	N/A
9/30/2018	862	8	58	93	N/A
6/30/2018	854	-4	66	103	N/A
3/31/2018	858	-3	N/A	105	N/A
12/31/2017	862	-3	N/A	108	N/A
9/30/2017	871	16	N/A	112	N/A
6/30/2017	879	35	N/A	117	N/A
3/31/2017	876	35	N/A	130	N/A
12/31/2016	872	35	N/A	142	N/A
9/30/2016	861	30	N/A	119	N/A
6/30/2016	850	26	N/A	95	N/A
3/31/2016	851	18	N/A	71	N/A
12/31/2015	853	9	N/A	46	N/A
9/30/2015	846	21	N/A	59	N/A
6/30/2015	839	32	N/A	72	N/A
3/31/2015	806	48	N/A	74	N/A
12/31/2014	773	64	N/A	76	N/A
9/30/2014	752	60	N/A	77	N/A
6/30/2014	730	56	N/A	78	N/A
3/31/2014	733	58	N/A	76	N/A
12/31/2013	736	61	N/A	74	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: VIRPDas prognostizierte Gewinnwachstum (10.8% pro Jahr) liegt über der Sparquote (1.4%).

Ertrag vs. Markt: VIRPDie Erträge des Unternehmens (10.8% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt French (12.6% pro Jahr).

Hohe Wachstumserträge: VIRPDie Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: VIRPDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt French (5.6% pro Jahr).

Hohe Wachstumseinnahmen: VIRPDie Einnahmen des Unternehmens (5.9% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: VIRPDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (13.9%).

Virbac Zukünftiges Wachstum

Future Kriterienprüfungen 2/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Virbac SA Just Beat Revenue Estimates By 6.0%

Virbac SA Revises Earnings Guidance for the Fiscal Year 2024

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Virbac SA Provides Earnings Guidance for the Year 2024

Price target increased by 11% to €327

Virbac SA Confirms Revenue Forecasts for the Year 2023

Recent updates

An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 47% Undervalued

Virbac SA Just Beat Revenue Estimates By 6.0%

Unpleasant Surprises Could Be In Store For Virbac SA's (EPA:VIRP) Shares

Virbac SA Revises Earnings Guidance for the Fiscal Year 2024

Virbac Sa Announces Chief Executive Officer Changes

Upcoming dividend of €1.32 per share

Why We Think Virbac SA's (EPA:VIRP) CEO Compensation Is Not Excessive At All

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?

Dividend of €1.32 announced

Virbac SA (EPA:VIRP) Investors Are Less Pessimistic Than Expected

Full year 2023 earnings released: EPS: €14.40 (vs €14.43 in FY 2022)

Virbac SA (ENXTPA:VIRP) acquired Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591).

Here's What Analysts Are Forecasting For Virbac SA (EPA:VIRP) After Its Yearly Results

Full year 2023 earnings: EPS misses analyst expectations

Virbac SA (ENXTPA:VIRP) entered into a definitive agreement to acquire Sasaea Holdings Co., Ltd. from ORIX Corporation (TSE:8591) for an enterprise value of approximately €280 million.

Virbac SA Provides Earnings Guidance for the Year 2024

Is Virbac SA (EPA:VIRP) Trading At A 23% Discount?

Now 21% undervalued

Virbac SA's (EPA:VIRP) Shares Climb 25% But Its Business Is Yet to Catch Up

Virbac SA to Report Fiscal Year 2023 Results on Mar 19, 2024

Price target increased by 11% to €327

Investor sentiment improves as stock rises 15%

Virbac (EPA:VIRP) Has A Pretty Healthy Balance Sheet

Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH.

Virbac SA (ENXTPA:VIRP) signed an agreement to acquire Globion India Private Limited from Suguna Foods Private Limited and Lohmann Animal Health GmbH.

First half 2023 earnings released: EPS: €8.86 (vs €9.18 in 1H 2022)

Virbac SA Confirms Revenue Forecasts for the Year 2023

Is There An Opportunity With Virbac SA's (EPA:VIRP) 40% Undervaluation?

Here's Why We Think Virbac (EPA:VIRP) Is Well Worth Watching

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Upcoming dividend of €1.32 per share at 0.5% yield

Does Virbac (EPA:VIRP) Deserve A Spot On Your Watchlist?

Is Virbac (EPA:VIRP) Using Too Much Debt?

Full year 2022 earnings released: EPS: €14.44 (vs €13.40 in FY 2021)

Are Investors Undervaluing Virbac SA (EPA:VIRP) By 34%?

Virbac SA to Report First Half, 2023 Results on Sep 14, 2023

Virbac SA to Report Fiscal Year 2022 Results on Mar 23, 2023

Virbac SA (EPA:VIRP) Shares Could Be 50% Below Their Intrinsic Value Estimate

Price target decreased to €341

Investor sentiment deteriorated over the past week

Price target decreased to €348

Virbac SA Provides Revenue Guidance for the Year 2022

Does Virbac (EPA:VIRP) Have A Healthy Balance Sheet?

First half 2022 earnings released: EPS: €9.18 (vs €8.54 in 1H 2021)

Investor sentiment deteriorated over the past week

An Intrinsic Calculation For Virbac SA (EPA:VIRP) Suggests It's 42% Undervalued

These 4 Measures Indicate That Virbac (EPA:VIRP) Is Using Debt Safely

Upcoming dividend of €1.25 per share

Full year 2021 earnings: EPS exceeds analyst expectations

Virbac SA (EPA:VIRP) Shares Could Be 38% Below Their Intrinsic Value Estimate

We Think Virbac (EPA:VIRP) Can Manage Its Debt With Ease

Virbac SA (EPA:VIRP) Shares Could Be 36% Below Their Intrinsic Value Estimate

Virbac SA Provides Revenue Guidance for the Year 2022

Price target increased to €435

Here's Why I Think Virbac (EPA:VIRP) Is An Interesting Stock

Price target increased to €416

A Look At The Fair Value Of Virbac SA (EPA:VIRP)

Is Virbac (EPA:VIRP) Using Too Much Debt?

Here's Why I Think Virbac (EPA:VIRP) Might Deserve Your Attention Today

Investor sentiment improved over the past week

Price target increased to €367

Virbac SA (ENXTPA:VIRP) acquired an additional 15% stake in Centrovet group for $17.7 million.

Price target increased to €341

Is Virbac SA (EPA:VIRP) Trading At A 22% Discount?

Consensus EPS estimates increase to €10.34

Price target increased to €305

Virbac SA Raises Revenue Guidance for 2021